Catriona A. Ford

Catriona A. Ford

Auto-generated profile, based on publicly available information

Catriona A. Ford

Cancer Research UK Scotland Institute, Glasgow, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
JVJohan Vande Voorde
Johan Vande Voorde
RSRory T. Steven
Rory T. Steven
ANArafath K. Najumudeen
Arafath K. Najumudeen
CFCatriona A. Ford
Catriona A. Ford
ADAlexander Dexter
Alexander Dexter
OSOwen Sansom
Owen Sansom
The genomic landscape of colorectal cancer (CRC) is shaped by inactivating mutations in tumour suppressors such as APC , and oncogenic mutations such as mutant KRAS . Here we used genetically engineered mouse models, and multimodal mass spectrometry-based metabolomics to study the impact of common genetic drivers of CRC on the metabolic landscape of the intestine. We show that untargeted metabolic profiling can be applied to stratify intestinal tissues according to underlying genetic alterations, and use mass spectrometry imaging to identify tumour, stromal and normal adjacent tissues. By identifying ions that drive variation between normal and transformed tissues, we found dysregulation of the methionine cycle to be a hallmark of APC-deficient CRC. Loss of Apc in the mouse intestine was found to be sufficient to drive expression of one of its enzymes, adenosylhomocysteinase (AHCY), which was also found to be transcriptionally upregulated in human CRC. Targeting of AHCY function impaired growth of APC-deficient organoids in vitro, and prevented the characteristic hyperproliferative/crypt progenitor phenotype driven by acute deletion of Apc in vivo, even in the context of mutant Kras . Finally, pharmacological inhibition of AHCY reduced intestinal tumour burden in Apc Min/+ mice indicating its potential as a metabolic drug target in CRC.

24 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
MWMark White
Mark White
MMMegan L. Mills
Megan L. Mills
LMLaura M. Millett
Laura M. Millett
KGKathryn Gilroy
Kathryn Gilroy
YHYourae Hong
Yourae Hong
OSOwen Sansom
Owen Sansom
The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40–50%) and BRAF (10%) 1 , inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations 2–4 , we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras -mutant and Braf- mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras -driven and delayed resistance in Braf -driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF–RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.

16 October 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
SFSigrid K. Fey
Sigrid K. Fey
ANArafath K. Najumudeen
Arafath K. Najumudeen
DWDale Watt
Dale Watt
LMLaura M. Millett
Laura M. Millett
CFCatriona A. Ford
Catriona A. Ford
OSOwen Sansom
Owen Sansom
Pancreatic cancer is characterized by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered KRAS gene dosage drives progression and metastasis in pancreatic cancer. Whereas the role of oncogenic KRAS mutations is well characterized, the relevance of the partnering wild-type (WT) KRAS allele in pancreatic cancer is less well understood and controversial. Using in vivo mouse modeling of pancreatic cancer, we demonstrated that WT KRAS restrains the oncogenic impact of mutant KRAS and dramatically impacts both KRAS-mediated tumorigenesis and therapeutic response. Mechanistically, deletion of WT Kras increased oncogenic KRAS signaling through the downstream MAPK effector pathway, driving pancreatic intraepithelial neoplasia initiation. In addition, in the KPC mouse model, a more aggressive model of pancreatic cancer, lack of WT KRAS led to accelerated initiation but delayed tumor progression. These tumors had altered stroma and an enrichment of immunogenic gene signatures. Importantly, loss of WT Kras sensitized Kras mutant tumors to MEK1/2 inhibition though tumors eventually became resistant and then rapidly progressed. This study demonstrates the repressive role of WT KRAS during pancreatic tumorigenesis and highlights the critical impact of the presence of WT KRAS in both tumor progression and therapeutic response in pancreatic cancer. Significance: KRAS allelic status impacts pancreatic cancer progression and has the potential to guide effective treatment in a substantial subset of patients.

5 December 2024 in Cancer Research
Verified
Journal Article
Open access
CFCatriona A. Ford
Catriona A. Ford
DKDana Koludrovic
Dana Koludrovic
PCPatricia P. Centeno
Patricia P. Centeno
MFMona Foth
Mona Foth
ETElpida Tsonou
Elpida Tsonou
ACAndrew D. Campbell
Andrew D. Campbell
Metastatic melanoma remains a major clinical challenge. Large-scale genomic sequencing of melanoma has identified bona fide activating mutations in RAC1, which are associated with resistance to BRAF-targeting therapies. Targeting the RAC1-GTPase pathway, including the upstream activator PREX2 and the downstream effector PI3Kβ, could be a potential strategy for overcoming therapeutic resistance, limiting melanoma recurrence, and suppressing metastatic progression. Here, we used genetically engineered mouse models and patient-derived BRAFV600E-driven melanoma cell lines to dissect the role of PREX2 in melanomagenesis and response to therapy. Although PREX2 was dispensable for the initiation and progression of melanoma, its loss conferred sensitivity to clinically relevant therapeutics targeting the MAPK pathway. Importantly, genetic and pharmacologic targeting of PI3Kβ phenocopied PREX2 deficiency, sensitizing model systems to therapy. These data reveal a druggable PREX2/RAC1/PI3Kβ signaling axis in BRAF-mutant melanoma that could be exploited clinically. Significance: Cotargeting the MAPK and the PREX2/RAC1/PI3Kβ pathways has remarkable efficacy and outperforms monotherapy MAPK inhibition in BRAF-mutant melanoma, supporting the potential of this combination therapy for treating metastatic melanoma.

17 February 2025
Verified
Other
Open access
CFCatriona A. Ford
Catriona A. Ford
DKDana Koludrovic
Dana Koludrovic
PCPatricia P. Centeno
Patricia P. Centeno
MFMona Foth
Mona Foth
ETElpida Tsonou
Elpida Tsonou
ACAndrew D. Campbell
Andrew D. Campbell
Reverse Phase Protein Array antibodies

17 June 2026
Verified
Other
Open access
PDF file
SFSigrid K. Fey
Sigrid K. Fey
ANArafath K. Najumudeen
Arafath K. Najumudeen
DWDale Watt
Dale Watt
LMLaura M. Millett
Laura M. Millett
CFCatriona A. Ford
Catriona A. Ford
OSOwen Sansom
Owen Sansom
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.